Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results

Abstract Background We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria. Methods The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patien...

Full description

Bibliographic Details
Main Authors: Rosalinde E. R. Slot, Sander C. J. Verfaillie, Jozefien M. Overbeek, Tessa Timmers, Linda M. P. Wesselman, Charlotte E. Teunissen, Annemiek Dols, Femke H. Bouwman, Niels D. Prins, Frederik Barkhof, Adriaan A. Lammertsma, Bart N. M. Van Berckel, Philip Scheltens, Sietske A. M. Sikkes, Wiesje M. Van der Flier
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Alzheimer’s Research & Therapy
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13195-018-0390-y
Description
Summary:Abstract Background We aimed to describe the Subjective Cognitive Impairment Cohort (SCIENCe) study design, to cross-sectionally describe participant characteristics, and to evaluate the SCD-plus criteria. Methods The SCIENCe is a prospective cohort study of subjective cognitive decline (SCD) patients. Participants undergo extensive assessment, including cerebrospinal fluid collection and optional amyloid positron emission tomography scan, with annual follow-up. The primary outcome measure is clinical progression. Results Cross-sectional evaluation of the first 151 participants (age 64 ± 8, 44% female, Mini-Mental State Examination 29 ± 2) showed that 28 (25%) had preclinical Alzheimer’s disease (AD) (amyloid status available n = 114 (75%)), 58 (38%) had subthreshold psychiatry, and 65 (43%) had neither. More severe subjective complaints were associated with worse objective performance. The SCD-plus criteria age ≥ 60 (OR 7.7 (95% CI 1.7–38.9)) and apolipoprotein E (genotype) e4 (OR 4.8 (95% CI 1.6–15.0)) were associated with preclinical AD. Conclusions The SCIENCe study confirms that SCD is a heterogeneous group, with preclinical AD and subthreshold psychiatric features. We found a number of SCD-plus criteria to be associated with preclinical AD. Further inclusion and follow-up will address important questions related to SCD.
ISSN:1758-9193